BMS-908662
/ Exelixis
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
October 11, 2011
Study of XL281 in adults with solid tumors
(clinicaltrials.gov)
- P1, N=180; Recruiting → Completed; Completion date: Dec ’10 → Oct ’11
Completion date • Trial completion • Melanoma • Oncology
December 29, 2017
Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer
(clinicaltrials.gov)
- P1/2; N=17; Completed; Sponsor: Bristol-Myers Squibb; N=120 ➔ 17
Clinical • Combination therapy • Enrollment change
December 29, 2017
Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma
(clinicaltrials.gov)
- P1; N=8; Completed; Sponsor: Bristol-Myers Squibb; Active, not recruiting ➔ Completed
Clinical • Combination therapy • IO Biomarker • Trial completion
June 10, 2013
Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma
(clinicaltrials.gov)
- P1; N=8; Completed; Sponsor: Bristol-Myers Squibb; N=120 ➔ 8
Clinical • Combination therapy • Enrollment change • IO Biomarker
1 to 4
Of
4
Go to page
1